Bio Details

Ansbert Gadicke

Ansbert Gadicke is on the Board of Directors at Cullinan and a co-founder and Managing Director of MPM Capital and its venture capital activities as well as an investment committee member of its oncology-only crossover investment strategy (both public and private equities).

Ansbert co-founded MPM in 1997 with his partner Luke Evnin and was the lead investor and has served on the boards of several of MPM’s most successful investments including BioMarin, Idenix, Mitobridge, Pharmasset, and Radius. Prior to launching MPM’s venture investing activities, Ansbert led MPM’s Advisory and Investment Banking business, and previously, he was at The Boston Consulting Group.

Ansbert’s commitment to drug discovery and curing disease inspires his work both within and outside of MPM. In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Ansbert and Luke Evnin are recipients of the 2017 Global Oncology Visionary Award. He is a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.

Ansbert received an MD from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at MIT and the Biochemistry Department at Harvard University. While at the German Cancer Research Center he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.

Ansbert currently serves as Chairman of the Board at TCR2 Therapeutics and as a Board Director at ElevateBio and iTeos Therapeutics.